QTREX Quantum Ltd.

What they do

Inspira Technologies is focused on research, development, manufacturing and commercialization of proprietary life-support technologies for acute respiratory failure. Its development efforts aim to address limitations of traditional mechanical ventilators by enabling spontaneous breathing and potentially reducing the need for intubation and medically induced coma. The company is also pursuing collaborations with strategic partners, hospitals, medical device companies and distributors to support clinical evaluation and early adoption.

Revenue drivers

• Life-support technology products — The company's primary intended revenue source is its proprietary life-support technologies for acute respiratory failure; as of the 2025 fiscal year, annual revenue was $289,000.

Recent performance

For fiscal year 2025 ended December 31, 2025, Inspira reported revenue of $289,000, compared to no revenue in 2023 and 2024. Net loss was $13.2 million in 2025, versus $11.1 million in 2024 and $11.3 million in 2023. Diluted loss per share was $0.45 in 2025, an improvement from $0.60 in 2024 and $0.93 in 2023. Operating cash outflow was $9.9 million in 2025, compared with $9.4 million in 2024 and $9.7 million in 2023. At December 31, 2025, total assets were $5.3 million, shareholders' equity was $2.3 million, and cash and equivalents were $3.2 million.

Strategy

The company's stated strategy is to develop and commercialize life-support technologies that offer alternatives or complements to mechanical ventilation. In parallel with pursuing regulatory approvals, Inspira is seeking collaborations with strategic partners, hospitals, medical device companies and distributors to support clinical evaluation and early adoption. Commercial efforts are intended to focus on intensive care units, general medical units, operating theaters, and smaller urban and rural hospitals. These efforts are intended to support broader market access and adoption of its life-support technologies.

Risks

• No product revenue history — The company generated only $289,000 in revenue in 2025 and had no revenue in 2023 and 2024, making future revenue dependent on successful development and commercialization.
• Persistent net losses — Inspira reported a net loss of $13.2 million in 2025 and has incurred annual net losses each year from 2021 through 2025, with no profitability to date.
• Negative operating cash flow — Operating cash outflows have been consistently negative, totaling $9.9 million in 2025 and $9.4 million in 2024, requiring external funding to sustain operations.
• Regulatory and clinical uncertainty — The company's technologies require regulatory approvals and clinical evaluation, with no guarantee that its life-support products will receive clearance or achieve market adoption.

Outlook

The filing does not provide specific future financial guidance. Management indicates it will continue development of its life-support technologies while pursuing regulatory approvals and strategic collaborations for clinical evaluation and potential early adoption. Commercial focus is expected to remain on intensive care units, general medical units, operating theaters, and smaller urban and rural hospitals.